...
机译:PX-866的多中心期I试验,一种口腔不可逆的磷脂酰肌醇3-激酶抑制剂,在先进的实体瘤患者中
MD Anderson Cancer Center Houston TX United States;
University of Colorado Cancer Center Mail Stop 8117 PO Box 6511 Aurora CO 80045 United States;
MD Anderson Cancer Center Houston TX United States;
University of Colorado Cancer Center Mail Stop 8117 PO Box 6511 Aurora CO 80045 United States;
MD Anderson Cancer Center Houston TX United States;
University of Colorado Cancer Center Mail Stop 8117 PO Box 6511 Aurora CO 80045 United States;
Oncothyreon Inc. Seattle WA United States;
Oncothyreon Inc. Seattle WA United States;
MD Anderson Cancer Center Houston TX United States;
University of Colorado Cancer Center Mail Stop 8117 PO Box 6511 Aurora CO 80045 United States;
Oncothyreon Inc. Seattle WA United States;
Oncothyreon Inc. Seattle WA United States;
MD Anderson Cancer Center Houston TX United States;
University of Colorado Cancer Center Mail Stop 8117 PO Box 6511 Aurora CO 80045 United States;
机译:PX-866的多中心期I试验,一种口腔不可逆的磷脂酰肌醇3-激酶抑制剂,在先进的实体瘤患者中
机译:西妥昔单抗有或无PX-866(一种不可逆的口服磷脂酰肌醇3激酶抑制剂)治疗复发或转移性头颈部鳞状细胞癌患者的II期随机试验
机译:多西他赛有或没有PX-866(一种不可逆的口服磷脂酰肌醇3-激酶抑制剂)治疗复发或转移性头颈部鳞状细胞癌患者的2期随机试验
机译:Ⅰ类磷脂酰肌醇3-激酶抑制剂ZSTK474对人乳腺癌细胞的多丝活动
机译:实体瘤患者口服后评估新型抗肿瘤药2-甲氧基雌二醇(2ME2)的药代动力学与药效关系,代谢和血浆蛋白结合。
机译:多西他赛有或没有PX-866(一种不可逆的口服磷脂酰肌醇3-激酶抑制剂)治疗复发或转移性头颈部鳞状细胞癌患者的2期随机试验
机译:PX-866的多中心期I试验,一种口腔不可逆的磷脂酰肌醇3-激酶抑制剂,在先进的实体瘤患者中